United Parcel Service Inc vs State Street SPDR S&P Biotech ETF — how do they compare? United Parcel Service Inc trades at $116.02 (market cap $96.18B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: United Parcel Service Inc pays a 5.8% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| UPS | XBI | |
|---|---|---|
Market Cap | $96.18B | — |
Volume | 2,288,643 | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $120.00 | $164.28 |
52-Week Low | $82.58 | $85.16 |
Enterprise Value | $119.04B | — |
Dividend Yield | 5.8% | — |
Signals from Pluang's Aura AI — not financial advice
UPS stock trades at $116.34, down 1.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 results due July 28, 2026. Revenue declined to $88.66 billion in 2025, but cost controls supported a net margin of 5.94% and strong ROE of 33.41%. The company maintains solid cash flow from operations of $8.45 billion and recently paid a $1.64 dividend.
Outlook is mixed: cost-cutting and potential Q2 earnings beat offer upside, but revenue pressure and Amazon's logistics expansion pose risks. Analysts are cautiously optimistic with a $112 consensus target, slightly below current price. Key investor focus is on Q2 results and updated guidance for second-half 2026 inflection point prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →